12 completed, 10 active not recruiting, 9 recruiting, 7 terminated. 35 Phase 1, 19 Phase 2, 1 Not applicable.
Follow Refractory B-Cell Non-Hodgkin Lymphoma: new trials by email Literature Review of Refractory B-Cell Non-Hodgkin Lymphoma trials Research Report on Refractory B-Cell Non-Hodgkin Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma Biospecimen Collection, Pomalidomide - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Recruiting | University of Michigan Rogel Cancer Center | 12 | 2026-08-26 | 2026-10-15 |
| A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma Biospecimen Collection, Cognitive Intervention, Electronic Health Record Review - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Multiple Myeloma | Not applicable | Recruiting | Ohio State University Comprehensive Cancer Center | 90 | 2026-04-28 | 2026-05-27 |
| Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma ONC-PluReceptor NK cells - Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2026-02-24 | 2026-10-07 |
| Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma Biospecimen Collection, Computed Tomography, Epcoritamab - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder | Phase 2 | Recruiting | Reem Karmali | 34 | 2025-07-25 | 2026-07-08 |
| Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy Interferon Beta-1A, X-Ray Imaging, Echocardiography - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Withdrawn | Fred Hutchinson Cancer Center | 2025-04-01 | 2024-07-12 | |
| T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) EB103 - B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins | Phase 1 / Phase 2 | Recruiting | Estrella Immunopharma, Inc. | 27 | 2024-06-01 | 2026-10-01 |
| A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma LUCAR-20SP cells - Relapsed B-cell Non-Hodgkin Lymphoma, Refractory B-cell Non-Hodgkin Lymphoma | Phase 1 | Recruiting | Peking University Cancer Hospital & Institute | 42 | 2024-03-14 | 2025-03-25 |
| Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma Anti-CD19-CAR CMV-specific T-lymphocytes, Biospecimen Collection, Bone Marrow Biopsy - High Grade B-Cell Non-Hodgkin's Lymphoma, Intermediate Grade B-Cell Non-Hodgkin's Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 15 | 2023-09-29 | 2026-03-05 |
| Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies Loncastuximab Tesirine, Bone Marrow Biopsy, Bone Marrow Aspiration - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Terminated | University of Washington | 11 | 2023-08-07 | 2026-06-15 |
| Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas ACALABRUTINIB, LISOCABTAGENE MARALEUCEL, Lymphodepleting chemotherapy - Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | Patrick C. Johnson, MD | 28 | 2023-03-01 | 2026-01-29 |
| Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment Belinostat, Biopsy Procedure, Biospecimen Collection - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 48 | 2023-03-01 | 2026-09-18 |
| Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma Biospecimen Collection, Computed Tomography, Decitabine and Cedazuridine - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 32 | 2022-11-03 | 2026-09-10 |
| CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563, Bendamustine, Biospecimen Collection - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Recruiting | Mayo Clinic | 25 | 2022-10-03 | 2026-06-09 |
| Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Lenalidomide, Ublituximab, Umbralisib - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 1 | Withdrawn | Yazeed Sawalha | 2022-09-30 | 2022-09-30 | |
| A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) Loncastuximab Tesirine, Polatuzumab Vedotin, Glofitamab - B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma | Phase 1 | Active not recruiting | ADC Therapeutics S.A. | 154 | 2022-06-17 | 2026-07-17 |
| Long-Term Follow-up Study Caribou-sponsored investigational therapy - Lymphoma, Non-Hodgkin, Relapsed Non-Hodgkin Lymphoma | Enrolling by invitation | Caribou Biosciences, Inc. | 150 | 2022-03-16 | 2026-03-12 | |
| CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL CpG-STAT3 siRNA CAS3/SS3, Radiation Therapy - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Withdrawn | City of Hope Medical Center | 2021-07-27 | 2024-04-25 | |
| CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) CB-010, Cyclophosphamide, Fludarabine - Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma | Phase 1 | Active not recruiting | Caribou Biosciences, Inc. | 72 | 2021-05-26 | 2026-10-19 |
| Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Polatuzumab Vedotin, Rituximab, Rituximab and Hyaluronidase Human - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma | Phase 2 | Terminated | Academic and Community Cancer Research United | 3 | 2021-04-01 | 2024-09-19 |
| Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies Modified anti-CD19 CAR T cells - Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Leukemia | Phase 1 | Unknown | Liqun Zou | 18 | 2021-03-17 | 2022-09-26 |
Showing 20 of 46. Sign in to see all of them.
Lymphoma, B-Cell (46) · Lymphoma, Follicular (13) · Lymphoma, Large B-Cell, Diffuse (13) · Lymphoma, Mantle-Cell (13) · Lymphoma, B-Cell, Marginal Zone (9) · Leukemia, Lymphocytic, Chronic, B-Cell (8) · Burkitt Lymphoma (7) · Lymphoma, Non-Hodgkin (7) · Lymphoma, T-Cell (7) · Hodgkin Disease (5) · Lymphoma (4) · Waldenstrom Macroglobulinemia (4) · Lymphoma, Primary Effusion (2) · Multiple Myeloma (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2)
Hemic and Lymphatic Diseases (46) · Immune System Diseases (46) · Immunoproliferative Disorders (46) · Lymphatic Diseases (46) · Lymphoproliferative Disorders (46) · Neoplasms (46) · Neoplasms by Histologic Type (46) · Lymphoma (42) · Lymphoma, Non-Hodgkin (39) · Hematologic Diseases (16) · Leukemia (11) · Disease Attributes (9) · Leukemia, Lymphoid (9) · Pathologic Processes (9) · Pathological Conditions, Signs and Symptoms (9)
Rituximab (10) · CT-P10 (8) · Specimen Handling (7) · Cyclophosphamide (6) · Magnetic Resonance Spectroscopy (6) · fludarabine (6) · Lenalidomide (5) · Biopsy (4) · Etoposide (3) · Leukapheresis (3) · fludarabine phosphate (3) · Carmustine (2) · Cytarabine (2) · Hyaluronoglucosaminidase (2) · MLN 8237 (2)
National Cancer Institute (NCI) (7) · Fred Hutchinson Cancer Center (6) · M.D. Anderson Cancer Center (4) · Mayo Clinic (3) · Academic and Community Cancer Research United (2) · Caribou Biosciences, Inc. (2) · City of Hope Medical Center (2) · A.O.U. Città della Salute e della Scienza (1) · ADC Therapeutics S.A. (1) · Affimed GmbH (1) · Barbara Ann Karmanos Cancer Institute (1) · Baylor College of Medicine (1) · CARsgen Therapeutics Co., Ltd. (1) · Estrella Immunopharma, Inc. (1) · Joseph Tuscano (1)
United States (38) · China (3) · Czechia (2) · Australia (1) · Belgium (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Poland (1) · Spain (1) · United Kingdom (1)
Ajay Gopal (3) · Catherine S Diefenbach (3) · Jordan Gauthier (2) · Ashley E Rosko, MD (1) · Barbara Botto, MD (1) · Carlos Ramos, MD (1) · Connor Johnson, MD (1) · Dipenkumar Modi, M.D. (1) · Grzegorz S Nowakowski (1) · Hun Lee (1) · Jennifer E Agrusa, MD (1) · Jennifer E Amengual (1) · Jie Jin, Dr. (1) · Joseph M Tuscano (1) · Joseph Tuscano (1)
PMID 34515338, PMID 28424162, PMID 31177537, PMID 33785483, PMID 36597128, PMID 39820359, PMID 40186077
P01CA044991 (3), P30CA015704 (3), P30CA033572 (3), P30CA015083 (2), P30CA016672 (2), P50CA097274 (2), UM1CA186689 (2), P01CA229086 (1), P30CA013330 (1), P30CA016058 (1), P30CA016087 (1), P30CA022453 (1), P30CA060553 (1), P30CA069533 (1), P30CA093373 (1)